Sonnet BioTherapeutics Holdings, Inc. (SONN) |
|
2.94 -0.08 (-2.65%)
|
09-26 16:00 |
|
Open: |
3 |
Pre. Close: |
3.02 |
|
High:
|
3.05 |
Low:
|
2.8804 |
|
Volume:
|
42,076 |
Market Cap:
|
5(M) |
|
|
|
Technical analysis |
as of: 2023-09-26 3:22:30 PM |
|
Short-term rate:
|
 |
| Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell. |
|
Mid-term rate:
|
 |
| Target: |
Six months: 6.04  One year: 7.7 |
| Support: |
Support1: 2.88 Support2: 2.39 |
| Resistance: |
Resistance1: 5.17 Resistance2: 6.59 |
| Pivot: |
3.56 |
| Moving Average: |
MA(5): 3.12 MA(20): 3.96
MA(100): 8.06 MA(250): 16.1 |
| MACD: |
MACD(12,26): -1  Signal(9): -1.1 |
| Stochastic oscillator: |
%K(14,3): 5.1 %D(3): 3.7 |
| RSI: |
RSI(14): 22.5 |
| 52-week: |
High: 66 Low: 2.88 |
| Average Vol(K): |
3-Month: 80 (K) 10-Days: 50 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SONN ] has closed above bottom band by 10.7%. Bollinger Bands are 71.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
3.1 - 3.13 |
3.13 - 3.14 |
|
Low:
|
2.87 - 2.9 |
2.9 - 2.92 |
|
Close:
|
2.98 - 3.02 |
3.02 - 3.05 |
|
Company Description |
|
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. |
Headline News |
Wed, 20 Sep 2023
Raymond James Analyst Upgrades Delek US Hldgs Price Target to 34 - Best Stocks
Tue, 19 Sep 2023
Sonnet BioTherapeutics Regains Nasdaq Minimum Bid Price ... - BioSpace
Fri, 01 Sep 2023
Sonnet BioTherapeutics Implements Reverse Stock Split - Nasdaq
Fri, 01 Sep 2023
Sonnet BioTherapeutics Holdings, Inc. (SONN) has risen 2220.00% Friday In Premarket Trading - InvestorsObserver
Thu, 31 Aug 2023
U.S. shares mixed at close of trade; Dow Jones Industrial Average ... - Investing.com Canada
Thu, 31 Aug 2023
Why Sonnet BioTherapeutics Stock (SONN) Is Getting Obliterated - Sonnet BioTherapeutics (NASDAQ:SONN) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Underperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
-15 (M) |
| Shares Float |
0 (M) |
|
% Held by Insiders
|
1.75e+006 (%) |
|
% Held by Institutions
|
1.48e+006 (%) |
|
Shares Short
|
0 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
-2.109e+007 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-49.75 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-13 |
|
Return on Assets (ttm)
|
23.1 |
|
Return on Equity (ttm)
|
-161 |
|
Qtrly Rev. Growth
|
80.2 |
|
Gross Profit (p.s.)
|
-154.5 |
|
Sales Per Share
|
-953.88 |
|
EBITDA (p.s.)
|
-5.2725e+007 |
|
Qtrly Earnings Growth
|
-2.256e+007 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
0 (M) |
Stock Valuations |
|
PE Ratio
|
-0.01 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-0.07 |
|
Price to Sales
|
-0.01 |
|
Price to Cash Flow
|
0 |
Stock Dividends |
|
Dividend
|
33620 |
|
Forward Dividend
|
16210 |
|
Dividend Yield
|
1124410% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
